技术支持

High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases. Mult Scler Relat Disord. 2023 Jun;74:104704. doi: 10.1016/j.msard.2023.104704.(IF 4.8)

The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial). Mult Scler. 2023 May;29(6):668-670. doi: 10.1177/13524585231161148. (IF 5.85)

Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and is not associated with persistent symptoms. Eur J Neurol. 2023 May;30(5):1371-1377. doi: 10.1111/ene.15707.(IF 6.28)

Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients. J Cereb Blood Flow Metab. 2023 Apr 27:271678X231172520. doi: 10.1177/0271678X231172520. (IF 6.96)

Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood. Clin Chem Lab Med. 2023 Jan 31;61(7):1245-1254. doi: 10.1515/cclm-2022-1181.(IF 8.49)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Alzheimers Res Ther. 2023 Mar 10;15(1):48. doi: 10.1186/s13195-023-01201-0.(IF 8.8)

The dynamics of plasma biomarkers across the Alzheimer's continuum. Alzheimers Res Ther. 2023 Feb 8;15(1):31. doi: 10.1186/s13195-023-01174-0.(IF 8.8)

Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy. NPJ Parkinsons Dis. 2023 Mar 15;9(1):40. doi: 10.1038/s41531-023-00481-5. (IF 9.3)

Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis. 2023 Feb 9;9(1):23. doi: 10.1038/s41531-023-00447-7.(IF 9.3)

Plasma Neurofilament Light Chain Predicts Mortality and Long-Term Neurological Outcomes in Patients with Intracerebral Hemorrhage. Aging Dis. 2023 Apr 1;14(2):560-571. doi: 10.14336/AD.2022.21020.(IF 9.96)

Rapid Activation of Neuroinflammation in Stroke: Plasma and Extracellular Vesicles Obtained on a Mobile Stroke Unit. Stroke. 2023 Mar;54(3):e52-e57. doi: 10.1161/STROKEAHA.122.041422.(IF 10.17)

Association of CSF and Serum Neurofilament Light and Glial Fibrillary Acidic Protein, Injury Severity, and Outcome in Spinal Cord Injury. Neurology. 2023 Mar 21;100(12):e1221-e1233. doi: 10.1212/WNL.0000000000206744.(IF 11.8)

Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. Neurology. 2023 Jul 4;101(1):38-45. doi: 10.1212/WNL.0000000000207115. (IF 11.8)

Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):428-435. doi: 10.1136/jnnp-2022-330709. (IF 13.65)

Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Apr 19:jnnp-2022-330796. doi: 10.1136/jnnp-2022-330796. (IF 13.65)

Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):420-427. doi: 10.1136/jnnp-2022-330619. (IF 13.65)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):411-419. doi: 10.1136/jnnp-2022-330540.(IF 13.65)

Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023 May 2;146(5):2029-2044. doi: 10.1093/brain/awad042.(IF 15.25)

Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimers Dement. 2023 Apr 20. doi: 10.1002/alz.13026. (IF 16.65)

Prospective evaluation of plasma phosphorylated tau in a real-life memory clinic in Thailand. Alzheimers Dement. 2023 Jun;19(6):2745-2749. doi: 10.1002/alz.13022.(IF 16.65)

Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest. Crit Care. 2023 Feb 24;27(1):74. doi: 10.1186/s13054-023-04355-3.(IF 19.33)

Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest. JAMA Neurol. 2023 Apr 1;80(4):388-396.(IF 29.9)

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023 Feb 6;80(3):287–97. doi: 10.1001/jamaneurol.2022.5250. (IF 29.9)

栏目